Subsequently, we detected the cell proliferation inhibition activities of XR-4 in different wild-type p53 cancer cell lines via the CCK-8 (Cell Counting Kit-8) assay, including LNCaP (prostate cancer), 22Rv1 (prostate cancer), HepG2 (liver cancer), HCT116 (colorectal cancer), MCF7 (breast cancer), and T24 (bladder cancer) cell lines. This evidence concerns the gene TP53 and urinary bladder carcinoma.